Engineering the brain tumor microenvironment enhances the efficacy of dendritic cell vaccination: implications for clinical trial design
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-06-01 / Clin. Cancer Res. 2011 Jul;17(14):4705-18Cancer stem cells: perspectives of new therapeutical approaches for breast cancer
/in Breast Cancer, Dendritic Cells, International Publications /von 2011-06-01 / Front Biosci (Schol Ed) 2011 Jun;3:1486-99Oncolytic viruses for the treatment of neuroendocrine tumors
/in International Publications, Newcastle Disease Virus /von 2011-05-30 / Horm. Metab. Res. 2011 Nov;43(12):877-83Immunotherapy for the treatment of prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-05-24 / Nat Rev Clin Oncol 2011 May;8(9):551-61Cancer-testis antigen, BORIS based vaccine delivered by dendritic cells is extremely effective against a very aggressive and highly metastatic mouse mammary carcinoma
/in Dendritic Cells, International Publications /von 2011-05-12 / Cell. Immunol. 2011;270(2):188-97Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer
/in Dendritic Cells, International Publications, Prostate Cancer /von 2011-05-10 / Clin. Cancer Res. 2011 Jul;17(13):4558-67Important role of interferon regulatory factor (IRF)-3 in the interferon response of mouse macrophages upon infection by Newcastle disease virus
/in International Publications, IOZK Veröffentlichungen, Newcastle Disease Virus /von 2011-05-09 / Int. J. Oncol. 2011 Aug;39(2):493-504Dendritic cell-based vaccination of patients with advanced pancreatic carcinoma: results of a pilot study
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2011-05-06 / Cancer Immunol. Immunother. 2011 Aug;60(8):1097-107Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy
/in Dendritic Cells, Glioblastoma, International Publications /von 2011-05-01 / J. Immunother. 2011 May;34(4):382-9
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de